Novartis stock stabilizes after trial setbacks as investor pushes for board shake-up
Published on 09/13/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG stock (ISIN CH0012005267) is showing signs of stabilizing after U.S.-listed shares plunged 14% on September 11, 2026, in the company’s worst single session in more than 20 years, wiping nearly USD 30 billion off its market value according to Stocktwits.
Trial failures trigger rare share-price slump
The main catalyst for the move has been back-to-back late-stage clinical trial setbacks in early September 2026, including a Phase 3 miss for pelacarsen in cardiovascular risk reduction and another Phase 3 failure for Del-Desiran in myotonic dystrophy type 1, as reported by The Pharma Letter and Stocktwits.
According to Stocktwits, U.S.-listed Novartis shares closed down 14% on September 11, 2026, marking the sharpest share drop in over two decades and putting NVS stock on track for its worst week in more than seven years.
Major shareholder demands governance changes
The steep decline has prompted calls for stronger governance. A major shareholder has publicly urged a shake-up of Novartis’s board to improve oversight after the share-price fall tied to the twin trial failures, as detailed by Medical Dialogues.
In the same report, Medical Dialogues notes that Novartis’s stock had already fallen about 3% on the previous trading day after pelacarsen results disappointed investors, before the subsequent 10% in intraday losses on the following day tied to the Del-Desiran failure, together contributing to the approximately 14% close-to-close drop reported for September 11, 2026.
Despite these setbacks, Novartis stated that its financial guidance remains unchanged and emphasized the breadth of its pipeline of experimental medicines, according to the company’s comments cited by Medical Dialogues.
Recent deal highlights pipeline partnerships
Alongside the clinical disappointments, Novartis continues to invest in external innovation. On September 8, 2026, the company paid USD 50 million to Monte Rosa Therapeutics as a milestone in a collaboration that could reach up to USD 2.1 billion in total value, as reported by Yahoo Finance.
Yahoo Finance highlights that the Monte Rosa deal offers upside tied to a portfolio of targeted protein degradation therapies, with Novartis’s milestone payment indicating continued strategic interest in high-potential early-stage assets despite the recent late-stage disappointments.
Recent financial performance and valuation context
While the latest compact search set does not surface a fresh Novartis investor-relations release within the last week, same-period coverage points back to recently reported quarterly results earlier in 2026 and a generally resilient earnings base. Historical context from these earlier 2026 results indicates that Novartis generated multi-billion dollar revenue per quarter and maintained double-digit margins; however, these figures precede September 13, 2026 and therefore are best treated as historical reference, not as the most current reporting snapshot.
Analyst data compiled by MarketBeat on September 13, 2026 shows that six analysts currently rate Novartis stock Buy and ten rate it Hold, with a consensus target price of USD 153.00 for the U.S.-listed ADR, compared with a recent opening price of USD 137.22.
That implies about 11.5% upside from USD 137.22 to the USD 153.00 consensus target as of the date cited by MarketBeat, underscoring that the market still sees room for recovery even after the sharp setback.
Institutional investor activity and risk perception
The same MarketBeat report notes that quantitative hedge fund Engineers Gate Manager LP opened a new position of 28,899 Novartis shares during the second quarter of 2026, valued at approximately USD 4,529,000 at the time of reporting, according to MarketBeat.
This institutional interest complements comments from Wall Street analysts following the Del-Desiran trial failure. As Stocktwits reports, analysts at Baird and RBC Capital discussed the broader implications of Novartis’s failed myotonic dystrophy study for peer company Dyne Therapeutics, illustrating how Novartis’s clinical outcomes can ripple across the sector’s risk assessments.
Stock performance and market backdrop
According to Stocktwits, NVS stock is roughly flat year-to-date despite the recent drop, which compresses the year’s earlier gains into a narrow range and leaves the shares trading closer to the lower end of their 12-month performance band.
MarketBeat’s snapshot notes that Novartis ADR shares opened at USD 137.22 with a twelve-month low of USD 121.57 and a twelve-month high of USD 170.46, putting the opening price about 12.9% above the 12-month low but roughly 19.5% below the 12-month high as of the cited date in that report from MarketBeat.
Closing price snapshot and investor view
On the primary listing at SIX Swiss Exchange in Zurich, Novartis shares most recently closed at a level that, when adjusted for currency and venue differences, aligns broadly with the USD 137.22 reference price for the ADR mentioned by MarketBeat, with trading volume and market capitalization reflecting the company’s status as one of Europe’s larger healthcare constituents as of the last completed trading day before September 13, 2026.
Novartis stock - key data
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
